GoAI
Get started
Catheter Precision, Inc. logo

Catheter Precision, Inc.

VTAK

AMEXHealthcareMedical - Devices

Open in GoAI

Previous close

$0.2093

−$0.0011 · -0.52%

Aug 21, 4:00 PM ET

VTAK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

57

Fair Value

Momentum

19

Strong Down

Sentiment

50

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
David A. Jenkins
Listed since
Sep 27, 2018
Employees
17

Market position

Day range

Current $0.2093

52-week range

Current $0.2093

Open
$0.21
Previous close
$0.2104
Volume
430.26K
0.06× average
Average volume
7.21M
Average daily volume
Market cap
563.54K USD
Beta
0.48
Market reference 1
50-day average
$0.5964
-64.91% below average
200-day average
$1.3176
-84.12% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.98B USD
EV / EBITDA
-115.8×
Earnings yield
-0.87%
Free cash flow yield
-0.42%

Profitability & efficiency

Return on equity
-243.59%
Return on assets
-108.34%
Return on invested capital
-87.56%

Financial health

Current ratio
0.1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends19360%-57708%-134777%-211846%Gross margin, FY2021: -6990.91%Gross margin, FY2022: -1050.00%Gross margin, FY2023: 93.21%Gross margin, FY2024: 90.00%Gross margin, FY2025: 92.31%Operating margin, FY2021: -133027.27%Operating margin, FY2022: -192578.57%Operating margin, FY2023: -17673.98%Operating margin, FY2024: -2676.90%Operating margin, FY2025: -1487.30%Net margin, FY2021: -113954.55%Net margin, FY2022: -191892.86%Net margin, FY2023: -15966.52%Net margin, FY2024: -3962.62%Net margin, FY2025: -2098.05%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -6990.91%. Gross margin FY2022 -1050.00%. Gross margin FY2023 93.21%. Gross margin FY2024 90.00%. Gross margin FY2025 92.31%. Operating margin FY2021 -133027.27%. Operating margin FY2022 -192578.57%. Operating margin FY2023 -17673.98%. Operating margin FY2024 -2676.90%. Operating margin FY2025 -1487.30%. Net margin FY2021 -113954.55%. Net margin FY2022 -191892.86%. Net margin FY2023 -15966.52%. Net margin FY2024 -3962.62%. Net margin FY2025 -2098.05%.

Income trends

Revenue

819K USD+95.00%

Operating income

−12.18M USD-8.34%

Net income

−17.18M USD-3.24%
Income trends across reported periods8.71M USD−22.86M USD−54.44M USD−86.01M USDRevenue, FY2021: 22K USDRevenue, FY2022: 14K USDRevenue, FY2023: 442K USDRevenue, FY2024: 420K USDRevenue, FY2025: 819K USDOperating income, FY2021: −29.27M USDOperating income, FY2022: −26.96M USDOperating income, FY2023: −78.12M USDOperating income, FY2024: −11.24M USDOperating income, FY2025: −12.18M USDNet income, FY2021: −25.07M USDNet income, FY2022: −26.87M USDNet income, FY2023: −70.57M USDNet income, FY2024: −16.64M USDNet income, FY2025: −17.18M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 22K USD. Revenue FY2022 14K USD. Revenue FY2023 442K USD. Revenue FY2024 420K USD. Revenue FY2025 819K USD. Operating income FY2021 −29.27M USD. Operating income FY2022 −26.96M USD. Operating income FY2023 −78.12M USD. Operating income FY2024 −11.24M USD. Operating income FY2025 −12.18M USD. Net income FY2021 −25.07M USD. Net income FY2022 −26.87M USD. Net income FY2023 −70.57M USD. Net income FY2024 −16.64M USD. Net income FY2025 −17.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue819K USD420K USD442K USD14K USD22K USD
Cost of goods sold63K USD42K USD30K USD161K USD1.56M USD
Gross profit756K USD378K USD412K USD−147K USD−1.54M USD
Research and development862K USD272K USD475K USD6.39M USD12.25M USD
Selling, general, and administrative12.08M USD11.35M USD17.12M USD16.25M USD15.48M USD
Operating expenses12.94M USD11.62M USD78.53M USD26.81M USD27.73M USD
Interest income34K USD81K USD347K USD——
Interest expense281K USD91K USD——10K USD
Depreciation and amortization2.12M USD2.11M USD2.08M USD421K USD1.4M USD
Operating income−12.18M USD−11.24M USD−78.12M USD−26.96M USD−29.27M USD
Net income−17.18M USD−16.64M USD−70.57M USD−26.87M USD−25.07M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+61.31%
11 comparable reports
Latest EPS result
-0.92
Estimate -19 · Beat by 95.16%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.69-10.59-25.88-41.16Q2 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual -1.35, estimate -38, surprise +96.45%, Beat. Q2 2025, reported May 12, 2025: actual -0.36, estimate -38, surprise +99.05%, Beat. Q3 2025, reported Aug 13, 2025: actual -0.38, estimate -34.2, surprise +98.89%, Beat. Q4 2025, reported Nov 12, 2025: actual -1.7, estimate -26.6, surprise +93.61%, Beat. Q1 2026, reported Mar 31, 2026: actual 1.53, estimate -20.9, surprise +107.32%, Beat. Q2 2026, reported May 18, 2026: actual -1.39, estimate -20.9, surprise +93.35%, Beat. Q3 2026, reported Aug 14, 2026: actual -0.92, estimate -19, surprise +95.16%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -13.3, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.01M2.05M1.09M121.55KQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual 149K USD, estimate 300K USD, surprise -50.33%, Miss. Q2 2025, reported May 12, 2025: actual 143K USD, estimate 300K USD, surprise -52.33%, Miss. Q3 2025, reported Aug 13, 2025: actual 212K USD, estimate 600K USD, surprise -64.67%, Miss. Q4 2025, reported Nov 12, 2025: actual 226K USD, estimate 1.2M USD, surprise -81.17%, Miss. Q1 2026, reported Mar 31, 2026: actual 238K USD, estimate 1.7M USD, surprise -86.00%, Miss. Q2 2026, reported May 18, 2026: actual 432K USD, estimate 1.6M USD, surprise -73.00%, Miss. Q3 2026, reported Aug 14, 2026: actual 1.02M USD, estimate 2M USD, surprise -49.05%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 2.8M USD, surprise —, Comparison unavailable.

VTAK peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

Continue in GoAI

Research VTAK

research.disclaimer